This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Happy Labor Day, people! Summer’s over. Have you booked for JPM26 travel yet?

A market opportunity on Covid

Invivyd, a small biotech company based in Massachusetts, is developing an experimental monoclonal antibody designed to protect against Covid-19 infection like a vaccine does, but without the real or perceived limitations of vaccines, particularly the politically damaged mRNA shots from Pfizer and Moderna.

To read the rest of this story subscribe to STAT+. Subscribe Log In

See Full Page